Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.F. Borel, G. Bauman, I. Chapman, P. Donatach, A. Fahr, E.A. Mueller, et al.
In vivo pharmacological effects of ciclosporin and some analogues.
Advances in Pharmacology, 35 (1996), pp. 115-246
[2.]
B. Kahan.
Cyclosporine.
N Engl J Med, 321 (1989), pp. 1725-1738
[3.]
J. Grevel.
Absorption of cyclosporine A after oral dosing.
Trans Proc, 18 (1986), pp. 9-15
[4.]
S. Ohlman, A. Lindholm, H. Hagglund, J. Sawe, B.D. Kahan.
On the intraindividual variabililty and chronobiology of cyclosporine pharmacokinetics in renal transplantation.
Eur J Clin Pharmacol, 44 (1993), pp. 265-269
[5.]
N.G. Best, A.K. Trull, K.K.C. Tan, K.L. Hue, D.J. Spiegelhalter, S.M. Gore, et al.
Blood cyclosporin concentrations and the short term risk of lung rejection following heart-lung transplantation.
Br J Clin Pharmacol, 34 (1992), pp. 315-320
[6.]
J. Vonderscher, A. Meinzer.
Rationale for the development of Sandimmun Neoral Trans Proc, 26 (1994), pp. 2925-2927
[7.]
A.J. Coukell, G.L. Plosker.
Cyclosporin microemulsion (neoral): a pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation.
Pharmacoeconomics, 14 (1998), pp. 691-708
[8.]
J.M. Kovarik, E.A. Mueller, J.B. Van Bree, W. Arns, E. Renner, K. Kutz.
Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients.
Ther Drug Monit, 16 (1994), pp. 232-237
[9.]
E.A. Mueller, J.M. Kovarik, J.B. Van Bree, A.E. Lison, K. Kutz.
Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients –a concentration-controlled comparison with the commercial formulation.
Transplantation, 57 (1994), pp. 1178-1182
[10.]
P. Keown, B.D. Kahan, A. Johnston, G. Levy, S.P. Dunn, F. Cittero, et al.
Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997).
Trans Proc, 30 (1998), pp. 1-100
[11.]
G.A. Levy.
C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral® formulation.
Biodrugs, 15 (2001), pp. 279-290
[12.]
P. Belitsky, G.A. Levy, A. Johnston.
Neoral absorption profiling: an evolution in effectiveness.
Transplant Proc, 32 (2000), pp. 45S-52S
[13.]
B.D. Kahan.
Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters.
Transplantation, 40 (1985), pp. 457-469
[14.]
B.D. Kahan.
Pharmacokinetics of cyclosporin formulations and their relationship to clinical outcomes.
Focus on Medicine, 13 (1998), pp. 3-6
[15.]
A. Lindholm, B.D. Kahan.
Influence of cyclosporine pharmacokinetics, trough concentrations and AUC monitoring on outcome after kidney transplantation.
Clin Trials Ther, 54 (1993), pp. 205-228
[16.]
B.D. Kahan, M. Welsh, L. Schoenberg, et al.
Variable absorption of cyclosporin.
Transplantation, 62 (1996), pp. 599-606
[17.]
A. Johnston, I. Skertis, J.T. Marsden, et al.
A limited sampling strategy for the measurement of cyclosporin AUC.
Trans Proc, 22 (1990), pp. 1345-1346
[18.]
A. Johnston, J.M. Kovarik, E.A. Mueller, D.W. Holt.
Predicting patients’ exposure to cyclosporin.
Trans Int, 9 (1996), pp. 305-307
[19.]
A. Johnston.
Sparse-sampling-a practical method for measurement of AUCs.
Focus on Medicine, 13 (1998), pp. 7-10
[20.]
K. Mahalti, I. Sketris, K. West, R. Panek, P. Belitsky.
Neoral monitoring by simplified sparse sampling AUC: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation.
Transplantation, 68 (1999), pp. 55-62
[21.]
P. Belitsky, S. Dunn, A. Johnston, et al.
Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients.
Clin Pharmacokinet, 39 (2000), pp. 117-125
[22.]
D. Grant, N. Kneteman, J. Tchervenkov, A. Roy, A. Tan, L. Hendricks, et al.
Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8).
Transplantation, 67 (2000), pp. 1133-1137
[23.]
Levy G, Burra P, Cavallari A, Duvoux C, Lake J, Mayer AD, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). 73(6). [en prensa] 2002
[24.]
G.A. Levy.
Two-hour cyclosporin concentration (C2) as a monitoring tool for Neoral.
Focus on Medicine, 13 (1998), pp. 19-22
[25.]
G.A. Levy, C. O’Grady, L.B. Lilly, et al.
Conversion to C-2 cyclosporine monitoring using Neoral immunosuppression in maintenance in liver transplant patients: improvement in renal function and hypertension [abstract].
Am J Transplant, 1 (2002), pp. 310
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
